Caribou Biosciences, Inc.
CRBU
Positions held
Your positionsCRBU isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $50.39M | Enterprise value | -$34.07M | Trailing P/E | — | Forward P/E | -0.40 |
| PEG | — | Price / book | 0.51 | Beta | 2.31 | Dividend yield | 0.00% |
| Revenue growth | -43.8% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -16.9% |
| Profit margin | 0.0% | ROE | -78.3% | ROA | -36.8% | Debt / equity | 0.27 |
| Current ratio | 6.49 | Free cash flow | -$59.61M | Analyst recommendation | buy | Mean target | $5.75 |
| 52w high | $3.54 | 52w low | $0.45 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.5M | $2.4M | $3.9M | $2.2M | $2.7M |
| Op margin | -1690.4% | -1096.4% | -722.0% | -1337.6% | -1328.4% |
| Net income | -$24.3M | -$25.1M | -$26.5M | -$27.5M | -$54.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$25.3M | -$26.3M | -$28.5M | -$29.4M | -$35.4M |
- Revenue -37% vs prior quarter ($1.5M vs $2.4M).
- Operating margin compressed to -1690.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | — |
| Op margin | -1220.5% | -1667.2% | -336.6% | -768.2% | — |
| Net income | -$148M | -$149M | -$102M | -$99.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$136M | -$167M | -$116M | -$106M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Caribou Biosciences Shares Fall After HC Wainwright Downgrade
2026-10-08 · In the hunt for reverse merger targets, Caribou could be prized game
2026-10-08 · HC Wainwright Downgrades Caribou Biosciences to Neutral From Buy
2026-10-07 · Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate
2026-10-07 · CAR-T specialist Caribou culls pipeline and seeks exit deal
2026-10-07 · Caribou Shares Fall After Plans to Evaluate Strategic Alternatives, Discontinue CAR-T Programs
2026-10-07 · Leerink Partners Downgrades Caribou Biosciences to Market Perform From Outperform, Price Target is $1
2026-10-07 · Top Premarket Decliners
2026-10-07 · CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs
2026-10-06 · Caribou Biosciences stock plunges 40% on halt of CAR-T programs
2026-10-06 · Caribou Biosciences to Evaluate Strategic Alternatives
Price (daily)
Full chart · RSI · MACD · patterns